Damien L. Smith

Damien L. Smith

Urology
2911 Chanticleer Avenue
Santa Cruz, CA 95065

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

Phase 1 trial of durvalumab (anti-PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma.

Phase 1 trial of durvalumab (anti-PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma.

Journal: Blood advances
Published: August 27, 2024

Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphoma.

Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphoma.

Journal: Blood advances
Published: December 27, 2023

Telomere dynamics during hibernation in a tropical primate.

Telomere dynamics during hibernation in a tropical primate.

Journal: Journal of comparative physiology. B, Biochemical, systemic, and environmental physiology
Published: September 12, 2023

Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T-Cell Lymphoma.

Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T-Cell Lymphoma.

Journal: The Journal of investigative dermatology
Published: November 22, 2022

Generation of a humanized afucosylated BAFF-R antibody with broad activity against human B-cell malignancies.

Generation of a humanized afucosylated BAFF-R antibody with broad activity against human B-cell malignancies.

Journal: Blood advances
Published: July 14, 2022

Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.

Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.

Journal: Blood
Published: January 05, 2022

Emerging CAR T Cell Strategies for the Treatment of AML.

Emerging CAR T Cell Strategies for the Treatment of AML.

Journal: Cancers
Published: December 31, 2021

Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma.

Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma.

Journal: Blood advances
Published: April 14, 2021

Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions.

Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions.

Journal: Cancer immunology, immunotherapy : CII
Published: April 06, 2020

CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies.

CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies.

Journal: Science translational medicine
Published: February 07, 2019

Targeting myeloid-derived suppressor cells for cancer immunotherapy.

Targeting myeloid-derived suppressor cells for cancer immunotherapy.

Journal: Cancer immunology, immunotherapy : CII
Published: August 28, 2017

Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol.

Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol.

Journal: BMC cancer
Published: June 09, 2017
Showing 1-12 of 24

Last Updated: 09/26/2026